Abstract:Heparinases are enzymes that selectively cleave heparin and heparan sulfate chains, via cleavage of the glycosidic linkage between hexosamines and uronic acids, producing disaccharide and oligosaccharide products. While heparin is well known as an anti-coagulant drug, heparin and heparan sulfate are also involved in biological processes such as inflammation, cancer and angiogenesis and viral and bacterial infections and are of growing interest for their therapeutic potential. Recently, potential roles of heparin and heparan sulfate in relation to COVID-19 infection have been highlighted. The ability of heparinases to selectively cleave heparin chains has been exploited industrially to produce low molecular weight heparin, which has replaced heparin in several clinical applications. Other applications of heparinases include heparin and heparan sulfate structural analysis, neutralisation of heparin in blood and removal of the inhibitory effect of heparin on various enzymes. Heparinases are known to inhibit neovascularization and heparinase III is of interest for treating cancer and inhibiting tumour cell growth. Heparinase activity, first isolated from Pedobacter heparinus, has since been reported from several other microorganisms. Significant progress has been made in the production, characterisation and improvement of microbial heparinases in response to application demands in terms of heparinase yield and purity, which is likely to extend their usefulness in various applications. This review focuses on recent developments in the identification, characterisation and improvement of microbial heparinases and their established and emerging industrial, clinical and therapeutic applications.

Bioengineered heparin: Advances in production technology

Advancements in Heparosan Production Through Metabolic Engineering Andimproved Fermentation

Optimization of Bioprocess Conditions Improves Production of a CHO Cell-Derived, Bioengineered Heparin.

Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin

Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy

clotting of blood in diseased vessels , and is therefore used to treat deep vein thrombosis and acute coronary syndrome

Biosynthetic production of anticoagulant heparin polysaccharides through metabolic and sulfotransferases engineering strategies

Control of the Heparosan N-deacetylation Leads to an Improved Bioengineered Heparin

Biomedical applications of engineered heparin-based materials

Production, characteristics and applications of microbial heparinases

Combinatorial One-Pot Chemoenzymatic Synthesis of Heparin.

Chemoenzymatic synthesis of ultralow and low-molecular weight heparins

Immobilized Enzymes to Convert N-sulfo, N-acetyl Heparosan to a Critical Intermediate in the Production of Bioengineered Heparin

High Cell Density Cultivation of Recombinant Escherichia coli Strains Expressing 2- O -Sulfotransferase and C5-Epimerase for the Production of Bioengineered Heparin

General Considerations for Diversifying Heparin Drug Products by Improving the Current Heparin Manufacturing Process and Reintroducing Bovine Sourced Heparin to the US Market

Heparin Mimetics As Potential Intervention for COVID-19 and Their Bio-Manufacturing

Recent advances in biotechnology for heparin and heparan sulfate analysis

Synthesis of bioengineered heparin by recombinant yeast Pichia pastoris

Chemobiocatalytic Synthesis of a Low-Molecular-Weight Heparin

Heparin: an Old Drug for New Clinical Applications.

From Farm to Pharma: An Overview of Industrial Heparin Manufacturing Methods